| 摘要 |
The invention relates to the pharmaceutical industry in general and to the industry involved in the manufacture of pharmaceutical products for the treatment of diabetes and the comorbidites thereof. The invention is advantageous over prior art compositions in that it enables long-term management of diabetic symptoms in order to maintain adequate glycaemic control, such as to produce a more powerful effect in relation to hyperglycaemia, thereby enabling a reduction in doses and, consequently, the individual collateral effects of the drugs utilised. In addition, the inventive composition improves insulin sensitivity of pancreatic beta receptors, simultaneously correcting insulin secretion disorders, and stimulates lipid metabolism, thereby improving the profile of same in the blood plasma. The composition is formed by a hypoglycaemic agent, glimepiride, and an anti-hypoglycaemic agent, pioglitazone. The composition contains between 5 and 2,500 mg pioglitazone and between 1 and 250 mg gl imepiride.
|
